medline.ch Onkologie Urologische Tumoren

conid:1879
-kaloNeDinamik-------------------------------------------jo
-session-------------------------------------------Array
(
    [ID_S] => IP: 3.237.16.173; DATE: 2023/06/09/ 10:52:32
    [tip] => 2
    [contentType] => db
    [ses_userid] => 2
    [thisMode] => 
    [level_0] => 2
    [level_1] => 15
    [level_2] => 3
    [level_3] => 0
    [level_4] => 0
    [level] => 2
    [nodetype] => 2
    [node_family_id] => 0
    [monitor] => content
    [id_contentit_from_php_file] => 1879
    [uniqueid] => 202306091052323237161734295
    [lang] => Lng1
    [contentId] => 1879
    [browser] => IE
    [clas_css] => 0
    [level_p] => 2
    [lng] => Lng1
    [nodetype_ci] => -1
    [usr] => 0
    [vazhdopunen] => po
    [search_for] => ("urogenital neoplasms"[Majr] OR (("neoplasm"[ti] OR neoplasms[ti] OR cancer[ti] OR carcinoma[ti] OR tumor[ti] OR tumour[ti] OR "secondary"[subheading:majr]) AND (bladder[ti] OR prostatic[ti] OR prostate[ti] OR testicular[ti] OR testis[ti] OR penile[ti] OR kidney[ti] OR renal[ti]))  AND ("practice guideline" OR systematic[sb] OR "clinical trials"[mesh] OR "meta analysis"[pt] OR "epidemiologic studies"[mesh] OR randomi* OR "meta analysis" OR "evidence based" OR placebo* OR "single blind" OR "double blind" OR "control group" OR "triple blind" OR study[ti] OR studies[ti] OR trial[ti] OR trials[ti] OR consensus OR placebo OR review[pt] OR "sensitivity and specificity"[MeSH Terms] OR diagnos*[Ti] OR diagnosis[MeSH:noexp] OR diagnostic *[MeSH:noexp] OR diagnosis,differential[MeSH:noexp] OR diagnosis[Subheading:noexp] OR accuracy[Title/Abstract] OR "predictive value"[Title/Abstract]) AND (english[language] OR german[language] OR french[language] OR italian[language] OR spanish[language]) NOT (veterinary[subheading] OR "genital neoplasms, female"[mesh])
)

medline.ch

En | De

Impressum | Feedback

Sie sind hier: Onkologie » Urologische Tumoren

09. Juni 2023

Kardiovaskuläre Erkrankungen

Muskuloskelettale Erkrankungen

Gynäkologische Tumoren

Schrift:

Seite 1 von 7704


	Artikel 1 - 20 / 154079

	Conditional survival does not improve over time in metastatic castration-resistant prostate cancer patients undergoing docetaxel. Prostate Modonutti D, Majdalany SE, Butaney M, Davis MJ, Corsi N, Sood A, Trinh QD, Cole AP, Rogers CG, Novara G, Abdollah F. PMID: 37290911 [PubMed - as supplied by publisher]
	Re: The Prevalence of Low-Value Prostate Cancer Screening in Primary Care Clinics: A Study Using the National Ambulatory Medical Care Survey. J Am Board Fam Med Takahashi T. PMID: 37290828 [PubMed - as supplied by publisher]
	The Impact of PSMA PET-Based Eligibility Criteria Used in the Prospective Phase II TheraP Trial in Metastatic Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy. J Nucl Med Karimzadeh A, Heck M, Tauber R, Solaris E, Nekolla S, Knorr K, Haller B, D'Alessandria C, Weber WA, Eiber M, Rauscher I. PMID: 37290796 [PubMed - as supplied by publisher]
	Elevated Body Mass Index Is Associated with Improved Overall Survival in Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen-Directed Radioligand Therapy. J Nucl Med Hartrampf PE, Mihatsch PW, Seitz AK, Solnes LB, Rowe SP, Pomper MG, Kübler H, Bley TA, Buck AK, Werner RA. PMID: 37290794 [PubMed - as supplied by publisher]
	Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial. Lancet Pal SK, Albiges L, Tomczak P, Suárez C, Voss MH, de Velasco G, Chahoud J, Mochalova A, Procopio G, Mahammedi H, Zengerling F, Kim C, Osawa T, Angel M, Gupta S, Khan O, Bergthold G, Liu B, Kalaitzidou M, Huseni M, Scheffold C, Powles T, Choueiri TK. PMID: 37290461 [PubMed - as supplied by publisher]
	Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial. J Clin Oncol Antonarakis ES, Park SH, Goh JC, Shin SJ, Lee JL, Mehra N, McDermott R, Sala-Gonzalez N, Fong PC, Greil R, Retz M, Sade JP, Yanez P, Huang YH, Begbie SD, Gafanov RA, De Santis M, Rosenbaum E, Kolinsky MP, Rey F, Chiu KY, Roubaud G, Kramer G, Sumitomo M, Massari F, Suzuki H, Qiu P, Zhang J, Kim J, Poehlein CH, Yu EY. PMID: 37290035 [PubMed - as supplied by publisher]
	International Society of Urological Pathology (ISUP) Consensus Conference on Current Issues in Bladder Cancer: Progresses and Challenges. Am J Surg Pathol van der Kwast TH, Bubendorf L, Cheng L. PMID: 37288838 [PubMed - as supplied by publisher]
	Therapeutic Approaches to Penile Cancer: Standards of Care and Recent Developments. Res Rep Urol White J, Mason R, Lawen T, Spooner J, Faria KVM, Rahman F, Ramasamy R. PMID: 37288454 [PubMed]
	Preoperative imaging accuracy in size determination of prostate cancer in men undergoing radical prostatectomy for clinically localised disease. Insights Imaging Ageeli W, Soha N, Zhang X, Szewcyk-Bieda M, Wilson J, Li C, Nabi G. PMID: 37286770 [PubMed]
	A systematic review on the efficacy of CBT interventions for the mental and sexual health of survivors of prostate cancer. Sex Med Rev Pieramico S, Castro R, Aguiar S, Bismarck F, Ferreira D, Carvalho J, Quinta Gomes AL, Nobre P. PMID: 37286525 [PubMed - as supplied by publisher]
	Novel sequential treatment strategy for patients with muscle-invasive bladder cancer (MIBC): intravesical recombinant BCG, followed by neoadjuvant chemoimmunotherapy, radical cystectomy plus pelvic lymphadenectomy and adjuvant immunotherapy - protocol of a multicentre, single arm phase 2 trial (SAKK 06/19). BMJ Open Petrausch U, Spahn M, Schneider M, Hayoz S, Rentsch CA, Rothschild S, Omlin A, Cathomas R. PMID: 37286312 [PubMed - in process]
	Obesity and renal cell carcinoma: biological mechanisms and perspectives. Semin Cancer Biol Venkatesh N, Martini A, McQuade JL, Msaouel P, Hahn AW. PMID: 37286114 [PubMed - as supplied by publisher]
	Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. Lancet Agarwal N, Azad AA, Carles J, Fay AP, Matsubara N, Heinrich D, Szczylik C, De Giorgi U, Young Joung J, Fong PCC, Voog E, Jones RJ, Shore ND, Dunshee C, Zschäbitz S, Oldenburg J, Lin X, Healy CG, Di Santo N, Zohren F, Fizazi K. PMID: 37285865 [PubMed - as supplied by publisher]
	Distinguishing Renal Cell Carcinoma From Normal Kidney Tissue Using Mass Spectrometry Imaging Combined With Machine Learning. JCO Precis Oncol Shankar V, Vijayalakshmi K, Nolley R, Sonn GA, Kao CS, Zhao H, Wen R, Eberlin LS, Tibshirani R, Zare RN, Brooks JD. PMID: 37285559 [PubMed - in process]
	Validation and implementation of a mobile app decision support system for prostate cancer to improve quality of tumor boards. PLOS Digit Health Ural Y, Elter T, Yilmaz Y, Hallek M, Datta RR, Kleinert R, Heidenreich A, Pfister D. PMID: 37285355 [PubMed]
	Biopsy Assessment of Oncologic Control Three Years Following Primary Partial Gland Cryoablation: A Prospective Cohort Study of Men with Intermediate Risk Prostate Cancer. J Urol Wysock JS, Rapoport E, Hernandez H, Gogaj R, Lepor H. PMID: 37285232 [PubMed - as supplied by publisher]
	A scoring diagnostic system based on biparametric ultrasound features for prostate cancer risk assessment. Quant Imaging Med Surg Liu X, Zhou H, Xu X, Li Y, Hong R, Huang K, Shi H, Li F. PMID: 37284097 [PubMed]
	Oligometastasis in Prostate Cancer: Can We Learn from Those "Excluded" from a Phase 2 Trial? Eur Urol Open Sci Glicksman RM, Murad V, Santiago AT, Liu Z, Ramotar M, Metser U, Berlin A. PMID: 37284049 [PubMed]
	Potential Carbon Savings with Day-case Compared to Inpatient Transurethral Resection of Bladder Tumour Surgery in England: A Retrospective Observational Study Using Administrative Data. Eur Urol Open Sci Phull M, Begum H, John JB, van Hove M, McGrath J, O'Flynn K, Briggs TWR, Gray WK. PMID: 37284039 [PubMed]
	Real-world retrospective study of immune checkpoint inhibitors in combination with radiotherapy or chemoradiotherapy as a bladder-sparing treatment strategy for muscle-invasive bladder urothelial cancer. Front Immunol Xu C, Zou W, Zhang L, Xu R, Li Y, Feng Y, Zhao R, Wang Y, Liu X, Wang J. PMID: 37283762 [PubMed - in process]

Artikel 1 - 20 / 154079

Seite 1 von 7704

Suchbegriffe

Benutzen Sie englische Suchbegriffe für Ihre Suche in medline.ch.

Übersetzungsproblem?

mehr >>



		Zeitfenster

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Datenschutzerklärung / Privacy Policy \| Werbung